VitalHub Reports Q2 2022 Financial Results with Record Revenue over $9.4M
11 Agosto 2022 - 7:37PM
VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI)
(OTCQX:VHIBF) announced today it has filed its Interim Condensed
Consolidated Financial Statements and Management's Discussion and
Analysis report for the three and six months ended June 30, 2022,
with the Canadian securities authorities. These documents may be
viewed under the Company's profile at www.sedar.com.
VitalHub’s Chief Executive Officer Dan Matlow
commented, “The Company’s positive momentum has continued into the
second quarter, as demonstrated by another record high revenue
result. We continue to see steady upward progress across all our
key indicators, with a healthy pipeline of new business and backlog
of closed sales that have not yet begun recognizing revenue.
Notably, we are experiencing strong organic growth in our annual
recurring revenue (ARR) numbers, as we continue to secure long
term, recurring contracts. We generated over $800,000 of organic
ARR growth in Q2/2022. This brings our total organic ARR
growth over the last eight quarters to approximately $6.8 million.
It should also be noted that our Q2 ARR growth does not include the
recently announced Ontario Solicitors General transaction, which we
expect to start generating revenue in the latter part of this
year.”
VitalHub’s quarterly investor conference call
will take place on Friday, August 12, 2022, at 9:00AM EST. To join
the call, please dial 1-888-664-6383 (Toll-Free
North America) or 416-764-8650 (Local – Toronto)
and enter confirmation number 51418625.
A replay of the call will be available until
Friday, August 19, 2022, and can be accessed by dialing
1-888-390-0541 (Toll-Free North America) or
416-764-8677 (Local – Toronto), using the replay
entry code 418625#.
Second Quarter 2022
Highlights
- Revenue of $9,477,464, an increase
of $3,685,282 or 64% from the comparative period in the prior
year.
- Gross profit as a percentage of
revenue for Q2 2022 was 83% compared to 77% in Q2 2021.
- ARR (1, 2) grew by $7,204,418 to
$31,219,508, achieving a 30% growth for the quarter ($7,645,906 or
32% on a constant currency basis) from Q2 2022 from Q1 2022.
- $823,506 or 3.43% organically,
- $6,748,747 or 28.10% through
acquisition and,
- $367,836 or 1.53% due to an
unrealized foreign exchange loss.
- EBITDA (2) of $1,023,686 compared
to $157,114 from the comparative period in the prior year.
- Adjusted EBITDA (2) of $1,866,563,
or 20% of revenue, compared to $1,053,686 or 18% of revenue from
the comparative period in the prior year.
- Cash on hand at June 30, 2022 was
$36,830,071 compared to $16,389,982 as at December 31, 2021.
- Cashflow from operations before
changes in working capital was $3,984,148 for the period as
compared to $647,032 for the same period last year.
- During the quarter, the Company
completed a bought deal offering with net proceeds of
$16,296,220.
- TREAT Electronic Health Record was
selected by the Ministry of the Solicitor General for an initial
six year contract valued at $9,000,000. TREAT will be used to
better track the essential medical information needed to
effectively treat inmates in provincially run adult correctional
facilities across Ontario.
(1) The Company defines annual
recurring revenue (“ARR”) as the recurring revenue expected based
on yearly subscriptions of the renewable software license fees and
maintenance services (2) Non-IFRS measure
Q2 2022 and 2020 Results
|
Three months ended |
Six months ended |
|
30-Jun-22 |
%Revenue |
30-Jun-21 |
%Revenue |
Change |
30-Jun-22 |
%Revenue |
30-Jun-21 |
%Revenue |
Change |
|
$ |
|
$ |
|
% |
$ |
|
$ |
|
% |
Revenue |
9,477,464 |
|
100% |
5,792,182 |
|
100% |
64% |
18,900,656 |
|
100% |
11,115,255 |
|
100% |
70% |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
1,605,282 |
|
17% |
1,321,428 |
|
23% |
21% |
3,079,861 |
|
16% |
2,599,527 |
|
23% |
18% |
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit |
7,872,182 |
|
83% |
4,470,754 |
|
77% |
76% |
15,820,795 |
|
84% |
8,515,728 |
|
77% |
86% |
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses |
|
|
|
|
|
|
|
|
|
|
|
General and administrative |
2,099,943 |
|
22% |
1,077,532 |
|
19% |
95% |
3,921,577 |
|
21% |
2,276,451 |
|
20% |
72% |
Sales and marketing |
1,023,250 |
|
11% |
917,407 |
|
16% |
12% |
2,071,639 |
|
11% |
1,672,037 |
|
15% |
24% |
Research and development |
2,694,514 |
|
28% |
1,294,271 |
|
22% |
108% |
4,742,759 |
|
25% |
2,452,444 |
|
22% |
93% |
Depreciation |
60,556 |
|
1% |
41,342 |
|
1% |
46% |
103,873 |
|
1% |
74,689 |
|
1% |
39% |
Depreciation of right-of-use assets |
52,094 |
|
1% |
67,193 |
|
1% |
(22%) |
115,482 |
|
1% |
130,764 |
|
1% |
(12%) |
Stock based compensation |
314,540 |
|
3% |
284,303 |
|
5% |
11% |
583,784 |
|
3% |
604,080 |
|
5% |
(3%) |
Foreign currency (gain) loss |
186,855 |
|
2% |
127,858 |
|
2% |
46% |
166,180 |
|
1% |
192,780 |
|
2% |
(14%) |
|
|
|
|
|
|
|
|
|
|
|
|
Other Income and Expenses |
|
|
|
|
|
|
|
|
|
|
|
Amortization of intangible assets |
795,270 |
|
8% |
546,845 |
|
9% |
45% |
1,479,198 |
|
8% |
980,816 |
|
9% |
51% |
Business acquisition, restructuring and integration
costs |
528,337 |
|
6% |
612,269 |
|
11% |
(14%) |
943,064 |
|
5% |
859,086 |
|
8% |
10% |
Interest expense and accretion (net of interest
income) |
110,405 |
|
1% |
(7,707 |
) |
(0%) |
(1533%) |
105,686 |
|
1% |
(18,294 |
) |
(0%) |
117% |
Interest expense from lease liabilities |
15,318 |
|
0% |
22,770 |
|
0% |
(33%) |
32,686 |
|
0% |
43,381 |
|
0% |
(24%) |
Loss on disposal of property and equipment |
1,057 |
|
0% |
0 |
|
0% |
0% |
1,057 |
|
0% |
2,497 |
|
0% |
(58%) |
|
|
|
|
|
|
|
|
|
|
|
|
Current and deferred income taxes |
(84,536 |
) |
(1%) |
10,071 |
|
0% |
100% |
41,365 |
|
0% |
10,071 |
|
0% |
311% |
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
74,579 |
|
1% |
(523,400 |
) |
(9%) |
114% |
1,512,194 |
|
8% |
(765,074 |
) |
(7%) |
(298%) |
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA (Non-IFRS measure) |
1,023,686 |
|
11% |
157,114 |
|
3% |
552% |
3,390,734 |
|
18% |
456,353 |
|
4% |
87% |
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA (Non-IFRS
measure) |
1,866,563 |
|
20% |
1,053,686 |
|
18% |
77% |
4,917,582 |
|
26% |
1,919,519 |
|
17% |
61% |
|
|
|
|
|
|
|
|
|
|
|
|
Annual Recurring Revenue (Non-IFRS
measure) |
31,219,508 |
|
|
15,931,628 |
|
|
96% |
31,219,508 |
|
|
15,931,628 |
|
|
49% |
|
|
|
|
|
|
|
|
|
|
|
|
Recurring revenue (Non-IFRS
Measure) |
7,232,646 |
|
76% |
4,628,927 |
|
80% |
56% |
12,965,537 |
|
69% |
8,497,284 |
|
76% |
34% |
|
|
|
|
|
|
|
|
|
|
|
|
Deferred revenue |
18,360,341 |
|
|
8,821,331 |
|
|
|
18,360,341 |
|
|
8,821,331 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash balance |
36,830,071 |
|
|
16,389,982 |
|
|
|
36,830,071 |
|
|
16,389,982 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ABOUT VITALHUB
Software for Health and Human Services providers
designed to simplify the user experience & optimize
outcomes.
Vitalhub provides technology to Health and Human
Services providers including; Hospitals, Regional Health
Authorities, Mental Health, Long Term Care, Home Health, Community
and Social Services. Vitalhub solutions span the categories of
Electronic Health Record (EHR), Case Management, Care Coordination,
Patient Flow & Operational Visibility, and DOCit Mobile
Apps.
The Company has a robust two-pronged growth
strategy, targeting organic growth opportunities within its product
suite, and pursuing an aggressive M&A plan. Currently, Vitalhub
serves 275+ clients across Canada, USA, UK, Australia, Qatar, and
Latvia. Vitalhub is based in Toronto, Canada, with an offshore
development hub in Sri Lanka. The Company is publicly traded on the
TSX Venture Exchange under the symbol “VHI”.
CAUTIONARY STATEMENT
This press release includes forward-looking
statements regarding the Corporation and its business, which may
include, but is not limited to, statements with respect to the
appointment of a new directors. Often, but not always,
forward-looking statements can be identified by the use of words
such as "plans", "is expected", "expects", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes" or variations
(including negative variations) of such words and phrases, or state
that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such statements
are based on the current expectations of the management of each
entity and are based on assumptions and subject to risks and
uncertainties. Although the management of each entity believes that
the assumptions underlying these statements are reasonable, they
may prove to be incorrect. The forward-looking events and
circumstances discussed in this release, may not occur by certain
specified dates or at all and could differ materially as a result
of known and unknown risk factors and uncertainties affecting the
companies, including risks regarding the technology industry,
failure to obtain regulatory or shareholder approvals, market
conditions, economic factors, the equity markets generally and
risks associated with growth and competition. Although the
Corporation has attempted to identify important factors that could
cause actual actions, events or results to differ materially from
those described in forward-looking statements, there may be other
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. No forward-looking statement
can be guaranteed. Except as required by applicable securities
laws, forward-looking statements speak only as of the date on which
they are made and the Corporation undertakes no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events, or otherwise.
CONTACT INFORMATION
Dan MatlowChief Executive Officer, Director(416)
727-9061dan.matlow@Vitalhub.com
Vitalhub (TSX:VHI)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Vitalhub (TSX:VHI)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025